Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation

Hsiao Hsin Sung Hsieh, Shailesh Agarwal, David J. Cholok, Shawn J. Loder, Kieko Kaneko, Amanda Huber, Michael T. Chung, Kavitha Ranganathan, Joe Habbouche, John Li, Jonathan Butts, Jonathan Reimer, Arminder Kaura, James Drake, Christopher Breuler, Caitlin R. Priest, Joe Nguyen, Cameron Brownley, Jonathan Peterson, Serra Ucer Ozgurel & 11 others Yashar S. Niknafs, Shuli Li, Maiko Inagaki, Greg Scott, Paul H. Krebsbach, Michael T. Longaker, Kenneth D Westover, Nathanael Gray, Jun Ninomiya-Tsuji, Yuji Mishina, Benjamin Levi

Research output: Contribution to journalArticle

Abstract

Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of transforming growth factor-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation. Upon identifying increased proliferation with loss of TAK1 signaling, we considered a regenerative approach to address insufficient tissue production through coordinated inactivation of TAK1 to promote cellular proliferation, followed by reactivation to elicit differentiation and extracellular matrix production. Although the current regenerative medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of drug withdrawal (“drug off”) implicit in these regimens is unknown. Because current TAK1 inhibitors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which allows us to study the response to targeted drug treatment (“drug on”) and subsequent withdrawal (“drug off”) through genetic modification, was used here to inactivate and reactivate Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off” (Flp-mediated reactivation) states during regenerative therapy using a mouse model with broad utility to study targeted therapies for disease. Stem Cells 2019;37:766–778.

Original languageEnglish (US)
Pages (from-to)766-778
Number of pages13
JournalStem Cells
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Transforming Growth Factors
Regeneration
Phosphotransferases
Pharmaceutical Preparations
Heterotopic Ossification
Regenerative Medicine
Wound Healing
Extracellular Matrix
Stem Cells
Cell Proliferation
Wounds and Injuries
Therapeutics

Keywords

  • Cellular proliferation
  • Differentiation
  • Progenitor cells
  • Proliferation
  • Stem/progenitor cell
  • Tissue regeneration

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Hsieh, H. H. S., Agarwal, S., Cholok, D. J., Loder, S. J., Kaneko, K., Huber, A., ... Levi, B. (2019). Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation. Stem Cells, 37(6), 766-778. https://doi.org/10.1002/stem.2991

Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation. / Hsieh, Hsiao Hsin Sung; Agarwal, Shailesh; Cholok, David J.; Loder, Shawn J.; Kaneko, Kieko; Huber, Amanda; Chung, Michael T.; Ranganathan, Kavitha; Habbouche, Joe; Li, John; Butts, Jonathan; Reimer, Jonathan; Kaura, Arminder; Drake, James; Breuler, Christopher; Priest, Caitlin R.; Nguyen, Joe; Brownley, Cameron; Peterson, Jonathan; Ozgurel, Serra Ucer; Niknafs, Yashar S.; Li, Shuli; Inagaki, Maiko; Scott, Greg; Krebsbach, Paul H.; Longaker, Michael T.; Westover, Kenneth D; Gray, Nathanael; Ninomiya-Tsuji, Jun; Mishina, Yuji; Levi, Benjamin.

In: Stem Cells, Vol. 37, No. 6, 01.06.2019, p. 766-778.

Research output: Contribution to journalArticle

Hsieh, HHS, Agarwal, S, Cholok, DJ, Loder, SJ, Kaneko, K, Huber, A, Chung, MT, Ranganathan, K, Habbouche, J, Li, J, Butts, J, Reimer, J, Kaura, A, Drake, J, Breuler, C, Priest, CR, Nguyen, J, Brownley, C, Peterson, J, Ozgurel, SU, Niknafs, YS, Li, S, Inagaki, M, Scott, G, Krebsbach, PH, Longaker, MT, Westover, KD, Gray, N, Ninomiya-Tsuji, J, Mishina, Y & Levi, B 2019, 'Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation', Stem Cells, vol. 37, no. 6, pp. 766-778. https://doi.org/10.1002/stem.2991
Hsieh, Hsiao Hsin Sung ; Agarwal, Shailesh ; Cholok, David J. ; Loder, Shawn J. ; Kaneko, Kieko ; Huber, Amanda ; Chung, Michael T. ; Ranganathan, Kavitha ; Habbouche, Joe ; Li, John ; Butts, Jonathan ; Reimer, Jonathan ; Kaura, Arminder ; Drake, James ; Breuler, Christopher ; Priest, Caitlin R. ; Nguyen, Joe ; Brownley, Cameron ; Peterson, Jonathan ; Ozgurel, Serra Ucer ; Niknafs, Yashar S. ; Li, Shuli ; Inagaki, Maiko ; Scott, Greg ; Krebsbach, Paul H. ; Longaker, Michael T. ; Westover, Kenneth D ; Gray, Nathanael ; Ninomiya-Tsuji, Jun ; Mishina, Yuji ; Levi, Benjamin. / Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation. In: Stem Cells. 2019 ; Vol. 37, No. 6. pp. 766-778.
@article{0320a4538fc7455db8eeeb7686f47896,
title = "Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation",
abstract = "Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of transforming growth factor-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation. Upon identifying increased proliferation with loss of TAK1 signaling, we considered a regenerative approach to address insufficient tissue production through coordinated inactivation of TAK1 to promote cellular proliferation, followed by reactivation to elicit differentiation and extracellular matrix production. Although the current regenerative medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of drug withdrawal (“drug off”) implicit in these regimens is unknown. Because current TAK1 inhibitors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which allows us to study the response to targeted drug treatment (“drug on”) and subsequent withdrawal (“drug off”) through genetic modification, was used here to inactivate and reactivate Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off” (Flp-mediated reactivation) states during regenerative therapy using a mouse model with broad utility to study targeted therapies for disease. Stem Cells 2019;37:766–778.",
keywords = "Cellular proliferation, Differentiation, Progenitor cells, Proliferation, Stem/progenitor cell, Tissue regeneration",
author = "Hsieh, {Hsiao Hsin Sung} and Shailesh Agarwal and Cholok, {David J.} and Loder, {Shawn J.} and Kieko Kaneko and Amanda Huber and Chung, {Michael T.} and Kavitha Ranganathan and Joe Habbouche and John Li and Jonathan Butts and Jonathan Reimer and Arminder Kaura and James Drake and Christopher Breuler and Priest, {Caitlin R.} and Joe Nguyen and Cameron Brownley and Jonathan Peterson and Ozgurel, {Serra Ucer} and Niknafs, {Yashar S.} and Shuli Li and Maiko Inagaki and Greg Scott and Krebsbach, {Paul H.} and Longaker, {Michael T.} and Westover, {Kenneth D} and Nathanael Gray and Jun Ninomiya-Tsuji and Yuji Mishina and Benjamin Levi",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/stem.2991",
language = "English (US)",
volume = "37",
pages = "766--778",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation

AU - Hsieh, Hsiao Hsin Sung

AU - Agarwal, Shailesh

AU - Cholok, David J.

AU - Loder, Shawn J.

AU - Kaneko, Kieko

AU - Huber, Amanda

AU - Chung, Michael T.

AU - Ranganathan, Kavitha

AU - Habbouche, Joe

AU - Li, John

AU - Butts, Jonathan

AU - Reimer, Jonathan

AU - Kaura, Arminder

AU - Drake, James

AU - Breuler, Christopher

AU - Priest, Caitlin R.

AU - Nguyen, Joe

AU - Brownley, Cameron

AU - Peterson, Jonathan

AU - Ozgurel, Serra Ucer

AU - Niknafs, Yashar S.

AU - Li, Shuli

AU - Inagaki, Maiko

AU - Scott, Greg

AU - Krebsbach, Paul H.

AU - Longaker, Michael T.

AU - Westover, Kenneth D

AU - Gray, Nathanael

AU - Ninomiya-Tsuji, Jun

AU - Mishina, Yuji

AU - Levi, Benjamin

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of transforming growth factor-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation. Upon identifying increased proliferation with loss of TAK1 signaling, we considered a regenerative approach to address insufficient tissue production through coordinated inactivation of TAK1 to promote cellular proliferation, followed by reactivation to elicit differentiation and extracellular matrix production. Although the current regenerative medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of drug withdrawal (“drug off”) implicit in these regimens is unknown. Because current TAK1 inhibitors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which allows us to study the response to targeted drug treatment (“drug on”) and subsequent withdrawal (“drug off”) through genetic modification, was used here to inactivate and reactivate Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off” (Flp-mediated reactivation) states during regenerative therapy using a mouse model with broad utility to study targeted therapies for disease. Stem Cells 2019;37:766–778.

AB - Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of transforming growth factor-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation. Upon identifying increased proliferation with loss of TAK1 signaling, we considered a regenerative approach to address insufficient tissue production through coordinated inactivation of TAK1 to promote cellular proliferation, followed by reactivation to elicit differentiation and extracellular matrix production. Although the current regenerative medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of drug withdrawal (“drug off”) implicit in these regimens is unknown. Because current TAK1 inhibitors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which allows us to study the response to targeted drug treatment (“drug on”) and subsequent withdrawal (“drug off”) through genetic modification, was used here to inactivate and reactivate Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off” (Flp-mediated reactivation) states during regenerative therapy using a mouse model with broad utility to study targeted therapies for disease. Stem Cells 2019;37:766–778.

KW - Cellular proliferation

KW - Differentiation

KW - Progenitor cells

KW - Proliferation

KW - Stem/progenitor cell

KW - Tissue regeneration

UR - http://www.scopus.com/inward/record.url?scp=85062968911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062968911&partnerID=8YFLogxK

U2 - 10.1002/stem.2991

DO - 10.1002/stem.2991

M3 - Article

VL - 37

SP - 766

EP - 778

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -